Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hymenoclea salsola pollen is a non-standardized allergenic extract derived from the pollen of the *Hymenoclea salsola* plant, commonly known as burrobrush or cheeseweed. Marketed by Greer Laboratories under the brand name Burrobrush, it is used for both the diagnosis and treatment of immediate hypersensitivity (Type I) allergies. For diagnostic purposes, it is used in skin testing (percutaneous or intradermal) to identify patients with specific IgE-mediated sensitivity to the plant's allergens. For therapeutic use, it is administered via subcutaneous immunotherapy (allergy shots) to induce immunological tolerance. The extract works by modulating the immune system's response to the allergen, typically shifting the balance from a Th2-mediated allergic response toward a Th1-mediated or regulatory T-cell response, thereby reducing clinical symptoms upon subsequent natural exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hymenoclea salsola pollen.